{"a":[{"_":"'Better every quarter': Bayer CEO stays course on turnaround plan as pharma sales underwhelm in Q2","$":{"href":"/pharma/better-every-quarter-bayer-ceo-stays-course-turnaround-plan-pharma-sales-underwhelm-q2","hreflang":"en"}}]}

Summary

Bayer reported Q2 earnings with pharma sales growth lagging behind crop science and consumer health divisions, prompting analysts to again consider potential structural changes to the German conglomerate. CEO reaffirmed commitment to turnaround plan despite underperformance.